| Home About Us Get Involved Join Stop TB USA World TB Day Partners Directory Resources TB Wire E-Newsletter Links |
|
| STOP TB USA was formerly known as the National Coalition for Elimination of Tuberculosis (NCET). Please pass this information on to your colleagues who are interested in TB elimination. |
|
10/15/08
Dear Colleague:
The 13th Annual Conference of the North American Region of the
International Union Against Tuberculosis and Lung Disease will
be held in February 26-28, 2009 in Vancouver, British Columbia,
Canada. The Abstract Committee is calling on submission of abstracts
for poster or oral presentations of research on all aspects of
tuberculosis control (including epidemiologic, clinical, basic
science, nursing, social, behavioral, psychosocial and educational
studies) to be presented at the 13th Annual Conference of the
North American Region of the IUATLD. Abstracts must be submitted
on or before October 31, 2008. Abstracts received after this
date will not be accepted. Forms are available at www.bc.lung.ca
. We will consider only abstracts submitted in accordance with
the guidelines. Sincerely
yours, 10/14/2008 From
Nuala Moore in the American Thoracic Society Washington (ATS)
Office: We have reached the final step in enactment of the Comprehensive
TB Elimination Act! The President signed the bill into law late
yesterday (October 13th). Congratulations all! The Self-Study
Modules on Tuberculosis are a series of educational modules designed
to provide information about tuberculosis (TB) in a self-study
format. This course is offered by the Centers for Disease Control
and Prevention (CDC), Division of Tuberculosis Elimination (DTBE).
The target audiences for this course are outreach workers, nurses,
physicians, administrators, health educators, and students from
a variety of settings, including TB programs, Managed care organizations,
Correctional facilities, Community-based organizations, Homeless
shelters, Migrant clinics, Substance abuse facilities, Nursing
and medical schools, and other facilities and programs serving
persons with or at risk for TB. Dear Partners
and Friends, We invite you to link to the latest issue of Stop
TB News. From RESULTS:
Recently, RESULTS took part in a major media event designed to
raise awareness of extensively drug-resistant TB. Images taken
by renowned photographer James Nachtwey were broadcast in major
public spaces, and featured on YouTube and Time magazine. Thousands
of people have signed our online letter urging the presidential
candidates to announce a major TB initiative upon taking office.
You can help by passing on the links to the slideshow, signing
the letter, or writing a letter to the editor of Time thanking
them for running the piece. These are exciting
times for the TB Alliance, as it expands to achieve its global
mission. Over the last year, we have seen the appointment of
our new President and CEO, Dr. Jerome Premmereur, a relocation
to a larger New York office, the hiring of Colleen Pero, our
first Chief Administrative Officer, and the start of an aggressive
recruiting strategy that will fuel the expansion in research
and development efforts. Our growing pipeline is anchored by
REMoxTB, the Phase III clinical trial of moxifloxacin-containing
regimens that was initiated at four sites in Africa this year.
REMoxTB is set to expand into Asia and Latin America, with 14
new sites accepted into the trial and expected to begin enrolling
over the next few months. Enrollment tracking and projections
have made the path forwards clear, and efforts to establish community
engagement programs in areas around the trial sites have been
intensified. Work to understand and influence market access now
encompasses the 22 high burden countries, and our policy work
continues to keep the need for new TB drugs high on the political
agenda. As we achieve success, we are planning for the needs
of the future by building new capabilities important to later
stage research and development, such as regulatory and project
management expertise. We continue to recruit additional talent
in discovery and clinical development to manage the larger portfolio,
the new research partnerships formed in 2008, and additional
projects that are now closer to the clinical stage of development.
Finally, we are forming a dedicated Market Access team to meet
the practical challenges of making new drugs and regimens available
to those who need them most. In the past three years our spending
on research and development has almost tripled, and the pattern
of steep growth is projected to continue through 2008 and beyond.
With the support and commitment of our partners, the TB Alliance
is proud to proclaim its growth and reaffirm its promise to develop
new, faster, better TB drugs that will be affordable and adopted. |
|
09/18/08
The 13h Annual Conference of the North American Region of the International Union Against Tuberculosis and Lung Disease (IUALTD) is scheduled for the Sheraton Vancouver Wall Centre Hotel in Vancouver, British Columbia, Canada on February 26 - 28, 2009. The Abstract Committee is calling
on submission of abstracts for poster or oral presentations of
research on all aspects of tuberculosis control (including epidemiologic,
clinical, basic science, nursing, social, behavioral, psychosocial
and educational studies) to be presented at the 13th Annual Conference
of the North American Region of the IUATLD. Abstracts must be
submitted on or before October 31, 2008. Abstracts received after
this date will not be accepted. Forms are available at www.bc.lung.ca
The committee will consider only abstracts submitted in accordance
with the guidelines. The committee is now accepting applications
for travel grant award for people from North, Central and South
America including the Caribbean and Haiti. Forms are available
on the above website. For more information, you may contact
Dr. Menn Biagtan at 604-731-5864 or at biagtan@bc.lung.ca. The Centers for Disease Control
and Prevention (CDC) Advisory Council for the Elimination of
Tuberculosis (ACET) will meet in Atlanta in Conference Rooms
A-C at Building 8 in Corporate Square on October 7 and 8, 2008.
These are open and public meetings. Topics will include: special
workgroup report/updates on TB in African Americans, Rapid TB
Drug Resistance Assay, and Bacille Calmette-Guerin (BCG). There
will also be updates on: CDC's State TB Cooperative Agreement
Formula; CDC Division of Global Migration and Quarantine's (DGMQ)
activities; Travel Restriction for TB Patients; Direct Specimen
Microscopy Restrictions - Implications for Early Diagnosis; and
New Isolation Guidelines. The TB Alliance has commissioned and edited a series of articles related to TB Drug Research and Development. The articles address key issues in TB drug research and development. These articles were commissioned and edited by the TB Alliance, and appear in a special issue of Tuberculosis. The articles appear in an August 2008 supplement to the journal and are available at:. http://www.tballiance.org/newscenter/view-latest-tb-news.php?id=802 These articles explore key aspects
and challenges in each phase of the TB drug research and development
process. Within discovery research, this includes target discovery
and validation, identification of new targets, lead optimization,
and choice of animal models. Clinical topics include discussions
of the pharmacokinetics and pharmacodynamics of TB drug candidates,
the role(s) of Early Bactericidal Activity studies, the design
of pivotal TB drug trials, and a regulatory perspective on developing
new drugs for multidrug-resistant TB (MDR-TB). |